Amazon Launches GLP-1 Weight Loss Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy HIMS?
Source: Newsfilter
- Increased Market Competition: Amazon's launch of the GLP-1 management program through One Medical integrates obesity treatment with routine care, likely pressuring shares of companies like Hims & Hers Health and Viking Therapeutics, which fell following the announcement.
- Transparent Pricing: The pricing for GLP-1 medications will start as low as $25 per month for insured patients, aiming to attract more customers by simplifying access to medications and enhancing market share.
- Convenient Drug Delivery: Amazon plans to expand same-day drug delivery to 4,500 cities by the end of 2026, leveraging its robust logistics network to improve customer experience and gain an edge in the competitive weight loss drug market.
- Diverse Treatment Options: Through Amazon Pharmacy, patients can access various GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, further driving the company's expansion into the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 30.560
Low
16.50
Averages
32.95
High
60.00
Current: 30.560
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- SpaceX Acquires Cursor: SpaceX is planning to acquire Cursor for $60 billion or pay $10 billion for collaboration, marking a significant move into the AI space, despite the complexities and potential delays associated with pre-IPO acquisitions, reflecting its ambition to transform into a tech giant.
- AI Strategic Shift: By partnering with Cursor, SpaceX aims to transition from a traditional rocket company to a tech engine that integrates space hardware with AI, addressing the significant energy and land requirements for AI computing, showcasing its long-term vision for space-based data centers.
- Amazon Enters GLP-1 Market: Amazon announced the introduction of GLP-1 medications to its platform, planning to offer same-day delivery in 4,500 cities, leveraging its robust logistics network and customer trust to disrupt traditional pharmacy markets and enhance consumer convenience in medication access.
- Competition in Healthcare: This move by Amazon could disrupt traditional pharmacies like CVS, and while challenges remain, its advantages in drug delivery and pricing strategies may attract more consumers, further solidifying its position in the healthcare sector.
See More
- Acquisition Details: SpaceX plans to acquire Cursor for $60 billion or pay $10 billion to support collaboration, indicating its ongoing expansion in the AI sector, although this deal may impact its upcoming $2 trillion IPO.
- AI Strategy Transformation: By partnering with Cursor, SpaceX aims to transition from a traditional rocket manufacturer to a tech giant that integrates AI with space hardware, attempting to address the electricity and space requirements facing AI today.
- Market Competitive Advantage: SpaceX's goal is to establish an unmatched space infrastructure that combines powerful rockets with advanced AI technology, despite facing a $1 billion monthly burn rate in its AI division and significant technical challenges.
- Investor Confidence Test: While SpaceX's valuation reaches $2 trillion, skepticism about its commercial viability and technical feasibility persists, potentially affecting investor confidence and the success of its IPO.
See More
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
- Intel Stock Surge: Intel (INTC) shares rose over 22% to a record high after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding expectations of $13.04 billion, thereby boosting overall confidence in the semiconductor sector and reflecting optimism about the economic potential of artificial intelligence.
- Consumer Confidence Rebound: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing expectations of 48.5, indicating an increase in consumer confidence which could stimulate spending and drive economic growth.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell over 1% amid expectations of renewed US-Iran talks, potentially exacerbating the global energy crisis and affecting operational costs and profit forecasts for energy-intensive sectors.
- Strong Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, demonstrating resilience in corporate profitability that may further boost market sentiment.
See More
- Comcast Downgrade: Comcast's stock fell nearly 8% after Deutsche Bank downgraded its rating from Buy to Hold, with analysts indicating that while there is visibility into sustainable revenue and EBITDA growth, they do not expect multiple expansion, highlighting challenges in a stable but non-growing business environment.
- HCA Healthcare Decline: HCA Healthcare's stock dropped over 7% due to a milder flu season resulting in fewer patient admissions, and although the company narrowly beat analyst profit estimates, investors are concerned about declining patient demand as Affordable Care Act subsidies phase out.
- Organon Surge: Organon's stock spiked 22% following a report from The Economic Times that Sun Pharma plans to submit a $13 billion offer for the U.S.-based company, which could significantly enhance Organon's market value and investor confidence.
- Intel Earnings Beat: Intel reported first-quarter earnings of 29 cents per share on revenue of $13.58 billion, both exceeding Wall Street expectations, leading to a stock rally of over 23%, indicating a strong recovery momentum in the semiconductor market that may boost overall industry investment enthusiasm.
See More
- Intel's Strong Outlook: Intel forecasts Q2 revenue between $13.8 billion and $14.8 billion, exceeding expectations of $13.04 billion, leading to a 22% stock surge that reignites optimism in the semiconductor sector, potentially driving increased investments and R&D across the industry.
- Market Optimism: The stock market is mostly higher as talks between the US and Iran appear to be resuming, with the Nasdaq 100 reaching an all-time high, reflecting investor expectations for reduced geopolitical risks, which may enhance market stability and investor confidence.
- WTI Oil Price Fluctuations: WTI crude oil prices fell over 1% after initially gaining 1% due to the US naval blockade on Iran, which could exacerbate the global energy crisis, impacting oil prices and the profitability of related companies, particularly in the Middle East.
- Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to rise 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains and bolster investor confidence.
See More











